{'fraction_non_alphanumeric': 0.02494061757719715, 'fraction_numerical': 0.00831353919239905, 'mean_word_length': 6.084033613445378, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Treatment of allergic conjunctivitis with ocular decongestants.

Three commercially available ocular decongestant products which contain varying concentrations of a vasoconstrictor (naphazoline hydrochloride) and an antihistamine (antazoline phosphate or pheniramine maleate) were tested for comfort and therapeutic efficacy. Three separate studies were performed: 1) a comfort comparison, 2) a vasoconstrictive efficacy test using an in vivo model of allergic conjunctivitis Induced by compound 48/80, and 3) a clinical trial of therapeutic efficacy In patients with allergic/hay fever conjunctivitis. The three preparations were found to vary greatly In patient comfort and acceptability, but were not different in their ability to amellorate the itching, tearing, redness, edema, and discomfort that occur In human allergic conjunctivitis.